BLUEPRINT MEDICINES CORP : Regulation FD Disclosure (form 8-K)

Item 7.01 Regulation FD.

On April 26, 2022, Charles A. Rowland, Jr. notified Blueprint Medicines Corporation (the "Company") of his resignation as a Class II member of the Company's board of directors (which includes his service on the compensation committee of the board of directors, and the audit committee of the board of directors, of which he is chair) effective immediately prior to the Company's 2022 annual meeting of stockholders. Mr. Rowland's resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

© Edgar Online, source Glimpses